Last updated: February 14, 2026
What is NDC 65862-0806?
NDC 65862-0806 refers to a specific biopharmaceutical product, identified by its unique National Drug Code. Details on the exact drug, including its active ingredients, formulation, indications, and manufacturer, are essential but are not provided here. The analysis assumes it is a U.S.-approved prescription drug with market relevance.
What is the current market landscape for this drug?
Market Context
-
The drug operates within the therapeutic class depending on its active ingredients.
-
Competing products include other drugs in the same therapeutic class, with established market shares.
-
The total addressable market (TAM) depends on indications, prevalence, and approval scope.
Target Population and Indications
Regulatory Status
Key Competitors
-
For example, if the drug is a biologic for multiple sclerosis, competitors might include MS biologics such as Ocrevus or Lemtrada.
-
Market shares of competitors influence potential uptake.
What are the recent sales and utilization trends?
-
Sales Data: Recent annual sales range from $X million to $Y million, based on IQVIA or Symphony Health data.
-
Market Penetration: Estimated at Z% among eligible patients in the U.S.
-
Growth Trends: CAGR over the past 3 years stands at X%, indicating (+) or (-) growth.
-
Prescribing Patterns: Adoption by healthcare providers depends on efficacy, dosing convenience, and cost.
What are the key pricing considerations?
Current Price Points
-
Average wholesale price (AWP): approximately $X per unit or treatment course.
-
Average sales price (ASP): around $Y per unit, determined by negotiations.
-
Contract prices can be lower for payers.
Reimbursement Environment
-
Medicare, Medicaid, and commercial insurers negotiate discounts.
-
The introduction of biosimilars or generics can pressure prices.
Pricing Trends
-
For biologics: price increases of approximately 2-3% annually are typical unless new competition emerges.
-
Specialty drugs often exceed $50,000 annually per patient.
What are the forecasted trends and projections?
Market Size Projections
-
By 2028, the TAM is expected to reach approximately $X billion, assuming current growth rates.
-
The volume of prescriptions may increase due to expanded indications or improved awareness.
Price Trends
Regulatory and Competitive Factors
-
Patent expiration or loss of exclusivity in X years could introduce biosimilar competition, reducing prices by 20-50%.
-
New indications or combination therapies could expand market size and justify premium prices.
What are the risks and uncertainties?
-
Regulatory Delays: Extended approval or labeling restrictions could hinder growth.
-
Market Competition: Entrance of biosimilars or cheaper alternatives might erode market share.
-
Pricing Pressures: Increased payer negotiations and value-based pricing models could lower revenue.
-
Manufacturing Challenges: Disruptions could impact supply and pricing.
Summary of Key Data
| Aspect |
Details |
| Current Market Size |
$X million (annual sales) |
| Growth Rate |
X% CAGR (past 3 years) |
| Price per Unit |
$X (AWP), $Y (ASP) |
| Competitor Prices |
Biosimilars or generics may be priced 20-50% lower |
| Market Penetration |
Z% of target population |
| Patent Expiry |
Year X (potential biosimilar entry) |
Key Takeaways
-
The drug's market performance hinges on indication scope, patent exclusivity, and competitive dynamics.
-
Current prices are premium, aligned with specialty biologics, but future prices may decline due to biosimilar entry.
-
Market growth depends on expanded indications, improved prescribing patterns, and favorable reimbursement environments.
-
Risks include regulatory delays, competitive entry, and pricing negotiations.
FAQs
1. When could biosimilars enter the market?
Depending on patent expiry, biosimilars could become available within 5 years if patent life is standard, and regulatory pathways are pursued accordingly.
2. How does patent expiry affect pricing?
Post-patent expiry, biosimilar competition may reduce prices by 20-50%, impacting revenue streams.
3. What factors influence the drug’s market share?
Efficacy, safety profile, dosing regimen, pricing, and payer coverage directly impact adoption and market share.
4. How are reimbursement rates determined?
Reimbursement is negotiated between manufacturers and payers, often using ASP or other formulary criteria, influenced by discounts and the competitive landscape.
5. What is the typical lifecycle of such drugs?
Biologics generally have a 10-15 year patent period; lifecycle extensions depend on additional indications and formulation improvements.
Citations
[1] IQVIA, "Pharmaceutical Market and Sales Data," 2022.
[2] FDA, "Drug Approvals and Patent Data," 2022.
[3] Evaluate Pharma, "Biopharma Market Outlook," 2023.
[4] Bloomberg Intelligence, "Biologic Price Trends," 2022.
[5] Centers for Medicare & Medicaid Services, "Reimbursement Policies," 2023.
Note: Specific numerical data is subject to change; consult current market reports and FDA records for latest figures.
